N0265041749.

Methods	Randomised trial (no further information) following stem cell collection Single centre RCT assessing superiority of TASCT
Participants	No information on planned or recruited number of patients age < 65 years Newly diagnosed (up to 3 months after diagnosis) patients with chemosensitive MM Salmon‐Durie stage II‐III
Interventions	Double vs single high‐dose melphalan (Treatment regimen Table 3)
Outcomes	OS, quality of life
Period and Location	Birmingham, Jan 1999 ‐ Jan 2001
Sample size calculation	NR
ITT analysis (n of drop‐outs)	NR
Notes	Register information (no clinical outcomes reported) According to principal investigator study failed to recruit a "sufficient number of patients"
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	NR
Allocation concealment (selection bias)	Unclear risk	NR
Blinding (performance bias and detection bias) All outcomes	Unclear risk	NR
Other bias	Unclear risk	NR